背景化疗与急性和长期心脏毒性相关,在临床上反映了心肌和血管内皮功能障碍,会引起心血管并发症.因此,在接受抗癌治疗的癌症患者中,心血管疾病的早期诊断对于提高长期生存率是必要的。我们在这项研究中的主要目标是辨别特定的抗癌化学疗法和生物制剂在给药前后对动脉僵硬度改变的影响。方法在穆斯塔法·巴查大学医院进行,阿尔及利亚,这项研究的重点是抗癌化疗患者的动脉僵硬度。评估包括血压,糖尿病,和血脂异常,使用经过验证的系统进行精确测量,特别是脉搏波速度(PWV)。应用了各种化疗方案,并使用R软件进行统计分析(R统计计算基金会,维也纳,奥地利)保持显著水平p=0.05。主要结果集中在颈动脉-股动脉PWV和次要终点,如中心和外周压力和脉压(PP)。使用适当的统计检验进行单变量和双变量分析。结果在58例接受抗癌化疗药物治疗的患者(34名女性和24名男性;平均年龄:52.64+/-12.12岁)中完成了一项比较前瞻性观察研究。我们的评估包括完整的临床检查,心电图,多普勒超声心动图,和压平眼压测量法,使用PWV测量动脉硬度。患者表现出显著较高水平的颈动脉-股动脉PWV,无论选择哪种化疗方案,停止治疗一年后没有恢复到初始水平(p值<0.01)。此外,这种增加在糖尿病和高血压患者以及接受单克隆抗体或插入剂治疗的患者中更为显著.结论本前瞻性研究显示化疗患者动脉僵硬度升高,强调需要评估PWV和监测心血管危险因素。使用PWV进行PP测量可以改善风险管理。
Background Chemotherapy correlates to acute and long-term cardiotoxicity, is reflected clinically by myocardial and vascular endothelial dysfunction, and can cause cardiovascular complications. Thus, early diagnosis of cardiovascular disease in cancer patients undergoing anti-cancer treatment is necessary to enhance long-term survival. Our principal objective in this study was to discern the impact of specific anti-cancer chemotherapeutics and biologics on arterial stiffness alterations before and after the administration. Methods Conducted at Mustafa Bacha University Hospital, Algeria, the study focused on arterial stiffness in anti-cancer chemotherapy patients. Assessments included blood pressure, diabetes, and dyslipidemia, with precise measurements using validated systems, particularly pulse wave velocity (PWV). Various chemotherapy protocols were applied, and statistical analysis with R software (R Foundation for Statistical Computing, Vienna, Austria) maintained a significance level of p=0.05. Key outcomes centered on carotid-femoral PWV and secondary endpoints such as central and peripheral pressures and pulse pressure (PP). Univariate and bivariate analyses were conducted using appropriate statistical tests. Results A comparative prospective observational study was completed on 58 patients (34 women and 24 men; mean age: 52.64 +/- 12.12 years) treated with anti-cancer chemotherapy agents. Our evaluation included a complete clinical exam, electrocardiogram, Doppler echocardiography, and applanation tonometry with arterial stiffness measurement using PWV. Patients presented significantly higher levels of carotid-femoral PWV, regardless of the chosen chemotherapy protocol, with no return to the initial level after one year of stopping treatment (p-value < 0.01). Moreover, this increase was more significant in patients with diabetes and hypertension and patients treated with monoclonal antibodies or intercalants. Conclusion This prospective study shows that chemotherapy patients have elevated arterial stiffness, emphasizing the need to assess PWV and monitor cardiovascular risk factors. PP measurement with PWV could improve risk management.